Protalix BioTherapeutics, Inc. · Biotech

PLX

Low riskNext report: Around Nov 12 (est.)

View price ↗

The short version

A company still losing money with growing sales, with elevated risk.

Going well

Sales up 27% in the latest quarter vs a year ago
No debt reported

Watch out for

About 15 months of cash left at its current burn
Share count growing 17.4% a year (dilution)
Losing money

Money moves

No insider buying or selling in the last 30 days
Institutions cut 14% from their holdings in the quarter ending June 2026 (57 bought, 33 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$2.47-3.1% that day

Company value: $199M; Share price times all shares
Price vs profit (P/E): 10.7x; You pay about $11 for each $1 of yearly profit
Price vs sales: 2.5x; Company value is 2.5 times a year of sales
Cash vs value: 14%; Cash as a share of company value

From PLX's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$19.9M+27% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $80.6M, up 30% from the 12 months before. Over 5 years, sales shrank about 3.5% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of PLX. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +30% a yearProfit margin23%Last 12 months: 23.5%P/E at the end11xToday: 10.7x. Many steady companies trade at 12x to 25xShare count change+10% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$299M

Profit in 5 years$69M

Price these guesses point to$5.84+136% vs $2.47 todayAbout +19% a year, before dividends

What today's price needs: with a 23% margin and a 11x P/E, sales would have to grow about 9.5% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/6Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-14.4%
PassDebt under half of equityNot relying on borrowed money.No debt reported
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-12.5%
MissProfitable every yearSteady profits, not one good year.2 of 10 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$13.6M
MissShare count not growingNot diluting owners. Falling means buybacks.+62.0% in 3 years

Revenue: $52.7M; -1.2% vs prior year
5-year growth: -3.5%/yr; revenue, per year
Total debt: None; 0.00x equity
Current ratio: 2.51x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 12

Revenue: $19.9M; +27.1% YoY
EPS: $0.05; vs $0.00
Op. margin: 23.5%; +16.0 pts
Gross margin: 61.0%; -1.5 pts
Free cash flow: -$11.0M
Share count: +1.6%; vs a year ago

Insider rating

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 1.1
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Steady-14.2%

Institutions cut 14.2% from their holdings. 57 bought, 33 sold.

Shares held by institutions14.5M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+4.0%

Cash runwayAt last year's cash burn

27 months

Debt to equityLatest balance sheet: debt compared with what owners have

No debt reported

Shares outstandingLatest reported

81M

Why low risk

Losing money

Earnings reports

Last 12

Next reportAround Nov 12 (est.)Estimated from the same quarter last year

Results filedAug 12
Results filedMay 13
Results filedMar 18
Results filedNov 13, 2025
Results filedAug 14, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

New 5%+ holder (passive)Oct 15 · View filing ↗Big holder

Insider trades

Open-market buys and sells, last 90 days

No open-market buys or sells in 90 days. Grants and option exercises are left out.

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

New 5%+ holder (passive)Oct 15 · Form SCHEDULE 13G ↗

Stock awardAharon SchwartzDirector

25,500 shares

Now owns 8,500 shares
Exercise price $2.59
Stock Options (Right to Buy)
2 transactions
Filed 6 days after trade

Sep 3Form 4 ↗

Stock awardEliot ForsterDirector

25,500 shares

Now owns 8,500 shares
Exercise price $2.59
Stock Options (Right to Buy)
2 transactions
Filed 1 day after trade

Sep 3Form 4 ↗

Stock awardZvi Shmuel BenDirector

25,500 shares

Now owns 8,500 shares
Exercise price $2.59
Stock Options (Right to Buy)
2 transactions
Filed 1 day after trade

Sep 3Form 4 ↗

Stock awardAmos Bar-shalevDirector

25,500 shares

Now owns 8,500 shares
Exercise price $2.59
Stock Options (Right to Buy)
2 transactions
Filed 1 day after trade

Sep 3Form 4 ↗

Stock awardDror BashanPRESIDENT AND CEO, Director

480,000 shares

Now owns 160,000 shares
Exercise price $2.59
Stock Option (Right to Buy)
2 transactions
Filed 1 day after trade

Sep 3Form 4 ↗

Stock awardPol F BoudesDirector

25,500 shares

Now owns 8,500 shares
Exercise price $2.59
Stock Options (Right to Buy)
2 transactions
Filed 1 day after trade

Sep 3Form 4 ↗

Insider tradeSep 4 · Form 4 ↗Insider tradeSep 4 · Form 4 ↗Insider tradeSep 4 · Form 4 ↗Earnings resultsAug 12 · Form 8-K ↗Quarterly reportAug 12 · Form 10-Q ↗Employee stock plan registrationAug 12 · Form S-8 ↗New 5%+ holder (passive)Jul 29 · Form SCHEDULE 13G ↗Shareholder vote resultsJun 25 · Form 8-K ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page